Immunovant(NASDAQ) IMVT

Immunovant makes medicines for people whose bodies attack their own healthy cells. These treatments help patients with serious immune system problems live more normal lives. The company focuses on a specific type of drug that clears harmful proteins from the blood.

Fighting Immune System Errors

• IMVT-1402: A lab-made protein designed to block a receptor that keeps harmful antibodies in the blood; currently in testing for several diseases.
• Subcutaneous Injection: A delivery method using a simple device for skin injections; designed for easy use by patients at home.
• Imeroprubart: The official medical name for the company's main drug candidate; it targets diseases in neurology and rheumatology.
• Autoimmune Solutions: Investigational treatments for conditions like Graves' disease and myasthenia gravis where the body attacks its own tissues.

Recent Strategic Shifts

• Stopped development of the drug candidate batoclimab in April 2026 to focus all resources on the newer IMVT-1402 program.
• Started major clinical trials for IMVT-1402 in Graves' disease and rheumatoid arthritis in December 2024.
• Moved core intellectual property between internal units during a corporate reorganization in January 2026.
• Maintains a key licensing partnership with HanAll Biopharma Co., Ltd. for the rights to its primary drug technologies.
• Launched a large study for Sjogren's disease in June 2025 to expand the use of its main treatment.

What Sets Immunovant Apart

The company uses a specialized device called the YpsoMate autoinjector to make its treatments easy for patients to use. Its main drug candidate aims to lower harmful antibody levels further than existing medicines without affecting other important blood proteins.

By the Numbers

• Net income reached -$110.6 million in Q3 2026, which narrowed from a -$111.1 million loss in Q3 2025.
• Operating income was -$114.4 million in Q3 2026, which worsened by 0.1% compared to the previous year.
• Free cash flow hit -$92.3 million in Q3 2026, an improvement from -$100.6 million in Q3 2025.
• Market capitalization reached $4.6 billion in Q3 2026, up 26.8% from $3.6 billion in the prior year.
• Revenue remained at $0 in Q3 2026 as the company has no products approved for sale yet.

The Path Ahead

Immunovant has transitioned from a multi-drug pipeline to focusing entirely on one promising treatment for several different diseases. This change centers the company's evolution on proving the clinical value of its most advanced technology across multiple medical fields.